Sedia Biosciences Receives $1.0 Million National Institutes of Health (NIH) Grant For New HIV Diagnostic Assay
2/12/2014 8:02:07 AM
PORTLAND, Ore.--(BUSINESS WIRE)--Sedia Biosciences Corporation of Portland, Oregon announced today that it has received a Notice of Award granting Phase II funding of its previous Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health. The Phase II funding is to continue development and commercialization for diagnostic use of Sedia’s HIV-1 Limiting Antigen (“LAg”)-Avidity EIA, a novel single well enzyme assay based on U.S. Centers for Disease Control and Prevention (“CDC”) licensed technology.
Help employers find you! Check out all the jobs and post your resume.
comments powered by